UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 10Q
(Mark One)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
    1934

                 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2008

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

            For the transition period from __________ to ___________

                        Commission file number: 333-107179

                          CANCER DETECTION CORPORATION
                          ----------------------------
             (Exact name of registrant as specified in its charter)


                            XPENTION GENETICS, INC.
                            -----------------------
                          (Former name of registrant)


          Nevada                                            98-0380519
  (State of Incorporation)                             (IRS Employer ID Number)


                    10965 Elizabeth Drive, Conifer, CO 80433
                    ----------------------------------------
                    (Address of principal executive offices)

                                 (303) 908-4900
                         (Registrant's Telephone number)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the past 12 months (or for such shorter  period that the registrant was required
to file such reports),  and (2) has been subject to the filing  requirements for
the past 90 days. Yes [X] No [ ]

Indicate by check mark whether the  registrant is a large  accelerated  file, an
accelerated filer, a non-accelerated  filer, or a smaller reporting company. See
the definitions of "large accelerated  filer,"  "accelerated filer" and "smaller
reporting company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer [  ]                              Accelerated filer [  ]
Non-accelerated filer  [  ] (Do not check if a smaller reporting company)
Smaller reporting company [X]

Indicate by check mark whether the  registrant is a shell company (as defined in
Rule 12b-2 of the Exchange Act). Yes [_] No [X]

Indicate the number of shares  outstanding  of each of the  issuer's  classes of
common stock, as of the latest practicable date:  4,828,124 shares of $0.001 par
value common stock outstanding as of October 20, 2008.


<PAGE>

<TABLE>
<CAPTION>

                          CANCER DETECTION CORPORATION
                                      INDEX

PART I - FINANCIAL INFORMATION

Item 1.  Financial Statements                                                       Page
                                                                                    ----
<S>                                                                                 <C>

Consolidated Balance Sheets - August 31, 2008 (unaudited) and May 31, 2008           3

Consolidated Statements of Operations - Three months ended August 31, 2008
        and 2007 and for the Period from Inception (October 13, 2004) to
        August 31, 2008 (unaudited)                                                  4

Consolidated Statements of Cash Flows - Three months ended August 31, 2008
        and 2007 and for the Period from Inception (October 13, 2004) to
        August 31, 2008 (unaudited)                                                  5

Notes to Financial Statements (unaudited)                                            6

Item 2. Management's Discussion and Analysis of Financial Condition
         and Results of Operations                                                  11

Item 3.  Quantitative and Qualitative Disclosures About Market Risk                 14

Item 4. Controls and Procedures                                                     14

Item 4T.  Controls and Procedures                                                   14

PART II - OTHER INFORMATION

Item 1.  Legal Proceedings                                                          15

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds                15

Item 3.  Defaults Upon Senior Securities                                            15

Item 4.  Submission of Matters to a Vote of Security Holders                        15

Item 5.  Other Information                                                          16

Item 6.  Exhibits                                                                   16

SIGNATURES                                                                          17

</TABLE>

                                       2

<PAGE>



                                     PART I

ITEM 1. FINANCIAL STATEMENTS

<TABLE>
<CAPTION>

                                 CANCER DETECTION CORPORATION
                              (formerly Xpention Genetics, Inc.)
                                (A Development Stage Company)
                                 CONSOLIDATED BALANCE SHEETS


                                                                                 August 31,            May 31,
                                                                                    2008                2008
                                                                               ----------------    ----------------
                                                                                 (Unaudited)

                                          ASSETS
<S>                                                                            <C>                 <C>
Current assets
     Cash and cash equivalents                                                           $ 155                $ 50
     Prepaid expenses                                                                    9,994                   -
                                                                               ----------------    ----------------
            Total assets                                                              $ 10,149                $ 50
                                                                               ================    ================


                         LIABILITIES AND STOCKHOLDERS' (DEFICIT)

Current liabilities
     Accounts payable and accrued expenses                                           $ 158,069           $ 149,664
     Accrued compensation                                                              368,000             344,000
     Accrued interest                                                                    2,010              17,344
     Advances from related parties                                                      43,750              15,000
     Notes payable, related party                                                            -             113,600
     Convertible debt                                                                   22,500              30,000
                                                                               ----------------    ----------------
            Total current liabilities                                                  594,329             669,608
                                                                               ----------------    ----------------

Stockholders' (deficit)
     Preferred stock, $0.001 par value, 10,000,000 shares authorized,
        none issued or outstanding                                                           -                   -
     Common stock, $0.001 par value, 100,000,000 shares authorized,
        4,828,124 and 2,998,826 shares issued and outstanding
        at August 31, 2008 and May 31, 2008, respectively                                4,828               2,999
     Additional paid-in capital                                                      1,104,323             978,101
     (Deficit) accumulated during the development stage                             (1,693,331)         (1,650,658)
                                                                               ----------------    ----------------
            Total stockholders' (deficit)                                             (584,180)           (669,558)
                                                                               ----------------    ----------------
            Total liabilities and stockholders' (deficit)                             $ 10,149                $ 50
                                                                               ================    ================


         The accompanying notes are an integral part of these consolidated financial statements.

                                               3
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                                  CANCER DETECTION CORPORATION
                               (formerly Xpention Genetics, Inc.)
                                  (A Development Stage Company)
                              CONSOLIDATED STATEMENTS OF OPERATIONS
                      for the three months ended August 31, 2008 and 2007,
             and for the period from Inception (October 13, 2004) to August 31, 2008


                                                                                                        October 13, 2004
                                                                                                         (Inception) to
                                                           2008                     2007                 August 31, 2008
                                                   ---------------------    ----------------------    ----------------------
<S>                                                <C>                      <C>                       <C>

Revenues                                                    $ -                      $          -              $          -
                                                   ---------------------    ----------------------    ----------------------

Expenses
    Research and development                                      1,580                    28,065                   939,181
    General and administrative                                   40,053                    38,874                   596,166
                                                   ---------------------    ----------------------    ----------------------
        Total expenses                                           41,633                    66,939                 1,535,347
                                                   ---------------------    ----------------------    ----------------------

Operating (loss)                                                (41,633)                  (66,939)               (1,535,347)
                                                   ---------------------    ----------------------    ----------------------

Other (expense)
    Interest expense                                             (1,040)                   (1,950)                  (23,384)
    Amortization of debt discount                                     -                    (5,293)                 (134,600)
                                                   ---------------------    ----------------------    ----------------------
           Total other (expense)                                 (1,040)                   (7,243)                 (157,984)
                                                   ---------------------    ----------------------    ----------------------


Net (loss)                                                    $ (42,673)                $ (74,182)             $ (1,693,331)
                                                   =====================    ======================    ======================

Basic and diluted:
  (Loss) per share                                              $ (0.01)                  $ (0.02)
                                                   =====================    ======================

  Weighted average shares outstanding                         4,231,614                 2,998,826
                                                   =====================    ======================





         The accompanying notes are an integral part of these consolidated financial statements.

                                               4
</TABLE>

<PAGE>

<TABLE>
<CAPTION>

                                  CANCER DETECTION CORPORATION
                               (formerly Xpention Genetics, Inc.)
                                  (A Development Stage Company)
                              CONSOLIDATED STATEMENTS OF CASH FLOWS
                      for the three months ended August 31, 2008 and 2007,
            and for the period from Inception (October 13, 2004) to August 31, 2008

                                                                                            October 13, 2004
                                                                                             (Inception) to
                                                          2008               2007           August 31, 2008
                                                     ---------------    ----------------    -----------------
<S>                                                  <C>                <C>                 <C>

Cash flows from operating activities:
      Net (loss)                                          $ (42,673)          $ (74,182)        $ (1,693,331)
                                                     ---------------    ----------------    -----------------
      Adjustments to reconcile net (loss) to
           net cash used in operating activities:
           Stock based compensation                               -                   -              371,400
           Amortization of debt discount                          -               5,293              134,600
      Changes in operating assets and liabilities:
           Increase in Prepaid expenses                      (9,994)            (14,343)              (9,994)
           Increase in Accounts payable and accrued
                expenses                                     31,522              58,982              542,530
                                                     ---------------    ----------------    -----------------
      Total adjustments                                      21,528              49,932            1,038,536
                                                     ---------------    ----------------    -----------------

           Cash flows (used in) operating activities        (21,145)            (24,250)            (654,795)
                                                     ---------------    ----------------    -----------------

Cash flows from financing activities:
      Proceeds from note payable                                  -                   -              113,600
      Proceeds from convertible debt                              -                   -               30,000
      Principal payments on convertible debt                 (7,500)                  -               (7,500)
      Advances from related parties, net                     28,750                   -               43,750
      Proceeds from issuance of common stock                      -                   -              475,100
                                                     ---------------    ----------------    -----------------
           Cash flows provided by financing activities       21,250                   -              654,950
                                                     ---------------    ----------------    -----------------

Net increase (decrease) in cash and equivalents                 105             (24,250)                 155

Cash and cash equivalents, beginning of period                   50              24,707                    -
                                                     ---------------    ----------------    -----------------

Cash and cash equivalents, end of period                      $ 155               $ 457                $ 155
                                                     ===============    ================    =================

Supplemental cash flow information:

        Income taxes paid                                       $ -                 $ -                  $ -
                                                     ===============    ================    =================

        Interest paid                                       $ 1,923                 $ -              $ 6,923
                                                     ===============    ================    =================


Non-cash investing and financing activities:

      Conversion of convertible debt and accrued
           interest to common shares                      $ 128,051                 $ -            $ 128,051
                                                     ===============    ================    =================


 The accompanying notes are an integral part of these consolidated financial statements.

                                       5
</TABLE>


<PAGE>


                          CANCER DETECTION CORPORATION
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 August 31, 2008
                                   (Unaudited)


NOTE  1.  ORGANIZATION,  BASIS  OF  PRESENTATION,  AND  SUMMARY  OF  SIGNIFICANT
ACCOUNTING POLICIES

Interim Financial Information

The interim consolidated financial statements included herein have been prepared
by the Company,  without audit,  in accordance with the rules and regulations of
the  Securities  and  Exchange  Commission  ("SEC")  pursuant  to  Item  210  of
Regulation S-X. Certain information and footnote  disclosures  normally included
in  financial  statements  prepared in  accordance  with  accounting  principles
generally  accepted  in the  United  States of  America  ("US  GAAP")  have been
condensed or omitted  pursuant to such SEC rules and  regulations,  although the
Company  believes  that  the  disclosures  included  are  adequate  to make  the
information presented not misleading.

In management's  opinion,  the consolidated balance sheets as of August 31, 2008
(unaudited)  and  May  31,  2008,  the  unaudited  consolidated   statements  of
operations  for the three month periods ended August 31, 2008 and 2007,  and the
unaudited  consolidated  statements  of cash flows for the three  month  periods
ended  August 31, 2008 and 2007,  contained  herein,  reflect  all  adjustments,
consisting  solely of normal recurring  items,  which are necessary for the fair
presentation of our financial position, results of operations, and cash flows on
a  basis  consistent  with  that of our  prior  audited  consolidated  financial
statements.  However,  the results of operations for interim  periods may not be
indicative of results to be expected for the full fiscal year. Therefore,  these
financial  statements  should be read in conjunction with the audited  financial
statements  and notes  thereto and summary of  significant  accounting  policies
included in the Company's Form 10-KSB for the year ended May 31, 2008.

Reverse Stock Split and Name Change

On September 10, 2008, the Board of Directors of the Company  approved a reverse
stock  split of the common  stock in the ratio of 1:20 and the name  change from
Xpention Genetics, Inc. to Cancer Detection Corporation.  The resolutions became
effective  September 17, 2008,  when the State of Nevada issued a Certificate of
Amendment to the Company's Articles of Incorporation.  The majority stockholders
had approved the reverse  split and the name change  amendment on July 25, 2008,
by written consent in lieu of a meeting of stockholders.

Organization

Cancer Detection Corporation (the "Company") (formerly Xpention Genetics,  Inc.)
is a Nevada  corporation  that  resulted from the business  combination  between
Xpention,  Inc.  and  Bayview  Corporation  that  occurred in March,  2005.  For
accounting purposes,  the date of inception for the Company is October 13, 2004,
the date that  Xpention,  Inc.  was  incorporated.  The  Company has been in the
development stage since its formation and has not yet realized any revenues from
its planned operations.  It is engaged in the biotechnology  industry to develop
both  immunological  and  molecular  tests for cancer  detection  in animals and
humans as well as  therapeutic  vaccines  and other  treatment  methods for both
canine and human cancers. The Company's fiscal year ends on May 31.

                                       6

<PAGE>

                          CANCER DETECTION CORPORATION
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 August 31, 2008
                                   (Unaudited)

Basis of Presentation

Cancer Detection  Corporation  represents the result of a merger between Bayview
Corporation  ("Bayview"),  a public  company,  and  Xpention,  Inc.,  a  private
company. During March 2005, Bayview issued 715,000 shares of its common stock to
the sole  shareholder  of  Xpention,  Inc. in exchange for all of the issued and
outstanding common shares of Xpention, Inc. pursuant to an Agreement and Plan of
Reorganization  (the  "Merger").  In addition,  concurrent  with the exchange of
shares,  Bayview  changed its name to Xpention  Genetics,  Inc.,  whose name has
subsequently been changed to Cancer Detection Corporation as described above.

For  accounting  purposes,  this  acquisition  of Xpention,  Inc. by Bayview,  a
non-operating  entity,  represents a reverse  acquisition  under which Xpention,
Inc. is  recognized as the  accounting  acquirer.  In substance,  the Merger was
recorded as a capital  transaction by the issuance of 2,127,159 shares of common
stock by the  Company  for all of the issued and  outstanding  common  shares of
Bayview. No goodwill or other intangible assets were recorded and the historical
financial  statements  as of and prior to the  acquisition  date  represent  the
operations of Xpention, Inc.

Xpention,  Inc. (a wholly-owned  subsidiary of the Company) was  incorporated in
the State of Colorado on October 13, 2004. Since its inception,  Xpention,  Inc.
has participated in the biotechnology industry to develop both immunological and
molecular  tests  for  cancer  detection  in  animals  and  humans  as  well  as
therapeutic  vaccines  and other  treatment  methods  for both  canine and human
cancers.

Bayview was  incorporated  in the State of Nevada,  on September  5, 2002.  From
inception  until  February  28,  2005,  Bayview  was  primarily  engaged  in the
acquisition and exploration of mining  properties,  but had ceased operations by
February  28, 2005.  As of the date of the Merger,  Bayview had no assets and no
operations and has been treated as the acquired company for accounting purposes.

Development Stage Company

The Company presents its financial  statements in conformity with the accounting
principles  generally  accepted  in the United  States of America  that apply to
enterprises  that are  establishing  their  operations.  As a development  stage
enterprise, the Company must utilize accounting principles consistent with those
required of an  established  enterprise,  and, in  addition,  must  disclose the
deficit  accumulated during the development stage and the cumulative  statements
of  operations  and cash flows from  commencement  of  development  stage to the
current balance sheet date.

Basis of Consolidation

The consolidated  financial  statements  include the accounts of the Company and
its  wholly-owned  subsidiary,   Xpention,  Inc.  All  significant  intercompany
accounts and transactions have been eliminated in consolidation.

                                       7

<PAGE>

                          CANCER DETECTION CORPORATION
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 August 31, 2008
                                   (Unaudited)

Use of Estimates

The preparation of the Company's financial statements in conformity with US GAAP
requires the Company's  management to make estimates and assumptions that affect
the amounts of assets and  liabilities,  the  identification  and  disclosure of
impaired  assets  and  contingent  liabilities  at the  date  of  the  financial
statements,  and the  reported  amounts  of  revenues  and  expenses  during the
reporting period. Actual results could differ from those estimates.

Per Share Amounts

SFAS 128,  "Earnings  Per Share,"  provides for the  calculation  of "Basic" and
"Diluted"  earnings per share. Basic earnings per share includes no dilution and
is computed by dividing net income (or loss) by the  weighted-average  number of
shares  outstanding  during the period.  Diluted earnings per share reflects the
potential  dilution  of  securities  that  could  share in the  earnings  of the
Company, assuming the issuance of an equivalent number of common shares pursuant
to options,  warrants,  or convertible debt  arrangements.  Diluted earnings per
share is not shown for  periods in which the  Company  incurs a loss  because it
would be  anti-dilutive.  Similarly,  potential common stock equivalents are not
included in the calculation if the effect would be anti-dilutive.

All per share amounts  presented herein have been restated to reflect the effect
of the 1 for 20 reverse stock split approved on September 10, 2008.

Recent Accounting Pronouncements

There were no accounting standards and interpretations issued recently which are
expected  to a have a  material  impact  on the  Company's  financial  position,
operations or cash flows.

NOTE 2.  GOING CONCERN

The  accompanying  consolidated  financial  statements  have  been  prepared  in
conformity  with US GAAP,  which  contemplates  continuation of the Company as a
going concern.

The Company is in its development stage and has not yet generated  revenues from
operations.  It has  experienced  losses  from  operations  as a  result  of its
investment  necessary to achieve its  operating  plan,  which is  long-range  in
nature.  For the three months ended August 31, 2008, the Company  incurred a net
loss of $42,673,  and has  incurred a  cumulative  net loss since  inception  of
$1,693,331.  At August 31, 2008, the Company had a working  capital  deficit and
stockholders'  deficit of $584,180.  These  conditions raise  substantial  doubt
about the ability of the Company to continue as a going concern.

Management does not believe that the Company's current capital resources will be
sufficient to fund its operating  activity and other  capital  resource  demands
during  fiscal year 2009 and is  currently  seeking  additional  resources.  The
Company's  ability to continue as a going concern is contingent upon its ability
to obtain capital through the sale of equity or issuance of debt,  joint venture
or sale of its assets, and ultimately attaining profitable operations.

                                       8

<PAGE>

                          CANCER DETECTION CORPORATION
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 August 31, 2008
                                   (Unaudited)

The financial  statements do not include any adjustments to reflect the possible
future effects on the recoverability and classification of assets or the amounts
and classification of liabilities that may result from the possible inability of
the Company to continue as a going concern.

NOTE 3.  NOTES PAYABLE, RELATED PARTY

Effective June 30, 2008, The Regency Group, LLC ("Regency  Group") converted the
outstanding principal of $113,600 and accrued interest of $14,451 into 1,829,298
shares of common stock.

NOTE 4.  CONVERTIBLE DEBT

Effective  January 5, 2007,  the Company  issued  convertible  debentures in the
aggregate  principal amount of $30,000 to two debt holders.  The debentures bear
interest  at 8% per annum and were  originally  due on January 5, 2008.  The due
date was subsequently  extended,  as discussed below. The debenture  holders may
convert the principal and accrued  interest into the Company's common stock at a
rate of $0.20 per share. Regency Group holds $15,000 of the convertible debt.

Both debt holders agreed to extend the due date of the convertible debentures to
April 30, 2008. During August 2008, the Company repaid one debt holder $7,500 in
principal plus accrued interest of $1,923.  In addition,  the debt holder agreed
to extend the due date of the remaining principal balance of $7,500 to September
30, 2008. On October 6, 2008, the Company repaid the remaining principal balance
of $7,500 plus accrued interest of $85 to the debt holder.  Regency Group agreed
to extend the due date of the $15,000 principal balance held by them to December
31, 2008.

NOTE 5.  STOCKHOLDERS' (DEFICIT)

On September 10, 2008 the board of directors approved a resolution to affect a 1
for 20 reverse stock split, which became effective  September 17, 2008, when the
State of Nevada issued a Certificate  of Amendment to the Company's  Articles of
Incorporation.  One share of common stock will be issued in  replacement of each
20 shares  outstanding  as of the July 24, 2008 record  date,  and the number of
authorized shares will remain the same. All of the financial information in this
report has been  adjusted to reflect  the effect of this 1 for 20 reverse  stock
split.

Effective  June 30, 2008, the Company issued  1,829,298  (post-split)  shares of
common stock for the  conversion of $113,600 in  outstanding  principal of notes
payable and the related accrued interest of $14,451.

NOTE 6.  RELATED PARTY TRANSACTIONS

During the three  months  ended  August 31,  2008,  the  Company  received  cash
advances of $28,750 from related parties.  The advances do not bear interest and
are due upon demand.

                                       9

<PAGE>

                          CANCER DETECTION CORPORATION
                       (Formerly Xpention Genetics, Inc.)
                          (A Development Stage Company)
                   NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
                                 August 31, 2008
                                   (Unaudited)

NOTE 7.  SUBSEQUENT EVENTS

Effective September 10, 2008, the Company recorded the issuance of 25,000 shares
of its common stock for investor relations services performed in connection with
the reverse  stock split and the name change.  The  services  were valued at the
post-split  share price at September  10,  2008,  of $0.22 per share for a total
expense of $5,500.

Subsequent to August 31, 2008, the Company issued 3,750,000 shares of its common
stock at $0.02 per share for cash proceeds of $75,000.

On October 6, 2008, the Company repaid the remaining principal balance of $7,500
and accrued interest of $85 on a convertible debenture.



















                                       10

<PAGE>

ITEM 2.  MANAGEMENT'S DISCUSSION AND ANALYSIS OR PLAN OF OPERATION

The  following  discussion  should  be read in  conjunction  with our  unaudited
financial  statements and notes thereto included herein. In connection with, and
because we desire to take  advantage  of, the "safe  harbor"  provisions  of the
Private  Securities  Litigation Reform Act of 1995, we caution readers regarding
certain forward looking statements in the following  discussion and elsewhere in
this report and in any other statement made by, or on our behalf, whether or not
in future filings with the Securities and Exchange  Commission.  Forward-looking
statements are statements not based on historical  information  and which relate
to future  operations,  strategies,  financial  results  or other  developments.
Forward looking  statements are necessarily based upon estimates and assumptions
that are inherently  subject to significant  business,  economic and competitive
uncertainties and  contingencies,  many of which are beyond our control and many
of which,  with  respect to future  business  decisions,  are subject to change.
These  uncertainties and contingencies can affect actual results and could cause
actual results to differ  materially from those expressed in any forward looking
statements  made by, or on our behalf.  We  disclaim  any  obligation  to update
forward-looking statements.

The  independent  registered  public  accounting  firm's report on the Company's
financial  statements  as of May 31,  2008,  and for  each of the  years  in the
two-year period then ended,  includes a "going concern"  explanatory  paragraph,
that describes  substantial  doubt about the Company's  ability to continue as a
going  concern.  Management's  plans in  regard  to the  factors  prompting  the
explanatory  paragraph are  discussed  below and also in Note 2 to the unaudited
interim financial statements.

Plan of Operation

The Company, through its wholly-owned subsidiary,  holds the exclusive worldwide
license to a patented  technology  for the  detection of cancer based on a tumor
marker known as "p65" which has been demonstrated to have elevated levels in the
blood of canine and human cancer conditions.  The tumor marker "p65" is believed
to be a protein  required  in the early  development  of  numerous  cancers  and
appears from early  research to provide a strong  indication  of tumor growth in
both canines and humans.  It also appears to have a direct  correlation to tumor
size/mass  making it a promising  marker for both early  detection  of malignant
tumor  formation as well as a useful tool for monitoring  therapy and remission.
We plan to  develop  an  immunological  test as well as a  molecular  assay  for
detection of cancer in canines.  We also plan to develop both  immunological and
molecular tests for detection of human cancers as well as therapeutic treatments
and vaccines.

We contract  with third party  research  organizations  to conduct our  research
activities.   During  June  2007,  we  entered  into  an  Assay  Revalidation  /
Redevelopment  Proposal with Future Focus, an independent testing  organization.
The project calls for third party validation of the research  results  presented
in the final report from the  University of Texas Health  Science  Center at San
Antonio  ("UTHSCSA")  and  technology  transfer of the current  assay plus assay
reformatting  and sample  analysis.  On August 15, 2007,  we announced  that the
researchers had been unable to replicate the results obtained at UTHSCSA.

                                       11

<PAGE>

As a result of the revalidation  results,  we are reviewing our planned research
activities for the development of an immunological canine cancer detection test.
We also continue to evaluate various options for  commercialization of products;
however,  it is  not  anticipated  that  we  will  generate  any  revenues  from
commercialization of our technology during the next twelve months.

Reverse Stock Split and Name Change

On September 10, 2008, the Board of Directors of the Company  approved a reverse
stock  split of the common  stock in the ratio of 1:20 and the name  change from
Xpention Genetics, Inc. to Cancer Detection Corporation.  The resolutions became
effective  September 17, 2008,  when the State of Nevada issued a Certificate of
Amendment to the Company's Articles of Incorporation.  The majority stockholders
had approved the reverse  split and the name change  amendment on July 25, 2008,
by written consent in lieu of a meeting of stockholders.

Liquidity and Capital Resources

As of August 31, 2008, our working  capital deficit of $584,180 was comprised of
current assets of $10,149 and current  liabilities of $594,329.  This represents
an improvement in working capital of $85,378 compared to the deficit of $669,558
at fiscal year end May 31, 2008.  The  conversion  of notes  payable and accrued
interest  improved our working capital  position.  During the three months ended
August 31, 2008, we consumed working capital while we pursued our business plan.

Management does not believe that the Company's current capital resources will be
sufficient to fund its operating  activity and other  capital  resource  demands
during  fiscal  year  2009.  Our  ability  to  continue  as a going  concern  is
contingent  upon our  ability to obtain  capital  through  the sale of equity or
issuance of debt,  joint  venture or sale of assets,  and  ultimately  attaining
profitable  operations.   There  is  no  assurance  that  we  will  be  able  to
successfully complete any one of these activities.

We are  presently  seeking  additional  debt and  equity  financing  to  provide
sufficient funds for payment of amounts due under research  contracts as well as
accrued but unpaid  professional  fees and  administrative  expenses and to fund
ongoing research and operations.

We have never received revenue from our operations.  We have historically relied
on equity and debt financings to fund our capital resource requirements. We have
experienced  net  losses  since  inception.  We do  not  believe  that  we are a
candidate for conventional  debt financing and we have not made  arrangements to
borrow  funds under a working  capital  line of credit.  We will be dependent on
additional financing to continue our research and development efforts.

All of our investment in research and development  activities has been expensed,
and does not appear as an asset on our balance  sheet.  From inception to August
31, 2008,  we have spent  $939,181 on our research  and  development  efforts to
commercialize the "p65" technology.

All of our  capital  resources  to date have been  provided  through the sale of
equity securities,  proceeds from notes payable and convertible debentures,  and
advances  from related  parties.  From  inception  through  August 31, 2008,  we
received  $475,100 in cash through  issuance of our common stock.  Since we have
not  generated  any cash from  operations,  we have relied on sale of equity and
borrowings to fund all of our capital needs.


                                       12

<PAGE>

Our ability to pay accounts payable and accrued expenses and repay borrowings is
dependent upon receipt of new funding from related parties,  private  placements
or debt financing.  Certain related parties have periodically  advanced funds to
us to meet  our  working  capital  needs.  The  related  parties  are  under  no
obligations to continue these advances. During the three months ended August 31,
2008, the related parties advanced an additional  $28,750 to us. These funds are
due on demand and do not accrue interest.

Net cash used in operating  activities was $21,145 during the three months ended
August 31,  2008,  compared to $24,250  during the three months ended August 31,
2007,  a decrease of $3,105.  During the three  months  ended August 31, 2008 we
incurred a net loss of $42,673.  This  compares to a net loss of $74,182 for the
three months  ended  August 31,  2007.  During the three months ended August 31,
2008 and 2007,  the  Company  did not  receive  or use  funds in its  investment
activities.

Net cash provided by financing  activities  during the three months ended August
31, 2008, was $21,250.  We received advances from related parties of $28,750 and
we repaid  outstanding  principal on convertible  notes payable of $7,500 during
the three months ended August 31, 2008.  We received no net cash from  financing
activities during the three months ended August 31, 2007.

Effective  June 30,  2008,  The  Regency  Group LLC  (Regency  Group)  converted
$113,600  of  outstanding  principal  on notes  payable  and  $14,451 of related
accrued  interest into  1,829,298  shares of our common stock.  During the three
months ended August 31, 2008, the due date of the remaining $15,000  convertible
debt to Regency Group was extended to December 31, 2008, and the due date of the
remaining  balance of $7,500 on a convertible debt was extended to September 30,
2008. The Company repaid the remaining  principal  balance of $7,500 and accrued
interest of $85 on October 6, 2008.

Results of Operations - Three Months Ended August 31, 2008 Compared to the Three
Months Ended August 31, 2007

We are considered a development stage company for accounting purposes,  since we
have not received any revenues  from  operations.  We are unable to predict with
any degree of  accuracy  when that  situation  will  change.  We expect to incur
losses until such time, if ever, as we begin generating revenue from operations.

For the three months ended August 31, 2008, we recorded a net loss of $(42,673),
or $(0.01) per share,  compared to a loss of  $(74,182) or $(0.02) per share for
the three months ended August 31, 2007.

Research and development costs were $1,580 for the three months ended August 31,
2008,  compared to $28,065  incurred  during the three  months  ended August 31,
2007, a decrease of $26,485.  The costs  incurred  during the three months ended
August 31, 2007  represent  third party testing to revalidate the results of the
research  report  from  UTHSCSA.  Our use of third  party  research  and testing
partners can result in variations in the expenses reported in each period.

General and  administrative  expense  increased  to $40,053 for the three months
ended  August 31,  2008,  compared to $38,874  during the same period of 2007, a
difference  of $1,179.  These  expenses  continue  to consist  primarily  of the
accrual for compensation costs,  professional fees associated with our status as
a public  company,  and the premium costs of D&O insurance.  Investor  relations
expense  increased from $575 to $2,617 as a result of costs  associated with the
reverse stock split and name change. D&O insurance  decreased by $1,395, or 29%,
as a result of obtaining a less costly policy.

                                       13

<PAGE>

Interest expense was $1,040 for the three months ended August 31, 2008, compared
to $7,243 for the three months  ended August 31, 2007, a decrease of $6,203,  or
85%.  Included in interest  expense in 2007 is the amortization of debt discount
in the amount of $5,293  related  to the  beneficial  conversion  feature of the
convertible  debentures  issued  during 2007.  The  remainder of the decrease in
interest  expense  is  attributable  to a  reduction  in  outstanding  principal
balances of notes  payable.  Effective  June 30, 2008,  Regency Group  converted
outstanding  principal  of  $113,600  to common  stock.  During  August 2008 the
Company  paid $7,500 of  outstanding  principal  balance on a  convertible  note
payable.

ITEM 3.  QUANTATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

Not applicable.

ITEM 4.  CONTROLS AND PROCEDURES

Disclosures Controls and Procedures

We have adopted and maintain disclosure controls and procedures (as such term is
defined in Rules 13a 15(e) and 15d-15(e)  under the  Securities  Exchange Act of
1934,  as  amended  (the  "Exchange  Act"))  that are  designed  to ensure  that
information  required to be disclosed in our reports  under the Exchange Act, is
recorded,  processed,  summarized and reported within the time periods  required
under  the  SEC's  rules and forms  and that the  information  is  gathered  and
communicated to our management, including our Chief Executive Officer (Principal
Executive Officer) and Chief Financial Officer (Principal Financial Officer), as
appropriate, to allow for timely decisions regarding required disclosure.

As required by SEC Rule 15d-15(b),  our Chief  Executive  Officer carried out an
evaluation  under the supervision and with the  participation of our management,
of the effectiveness of the design and operation of our disclosure  controls and
procedures  pursuant  to  Exchange  Act Rule  15d-14 as of the end of the period
covered by this report. Based on the foregoing  evaluation,  our Chief Executive
Officer has concluded that our disclosure  controls and procedures are effective
in timely alerting them to material  information  required to be included in our
periodic SEC filings and to ensure that information  required to be disclosed in
our periodic SEC filings is  accumulated  and  communicated  to our  management,
including  our Chief  Executive  Officer,  to allow timely  decisions  regarding
required  disclosure as a result of the deficiency in our internal  control over
financial reporting discussed below.


ITEM 4T. CONTROLS AND PROCEDURES

Management's Quarterly Report on Internal Control over Financial Reporting.

Our management is responsible for establishing and maintaining adequate internal
control over financial  reporting for the company in accordance  with as defined
in Rules  13a-15(f)  and  15d-15(f)  under  the  Exchange  Act.  Our  management
conducted  an  evaluation  of the  effectiveness  of our  internal  control over
financial  reporting  based on the  framework  in Internal  Control - Integrated
Framework  issued by the Committee of Sponsoring  Organizations  of the Treadway
Commission. Our internal control over financial reporting is designed to provide
reasonable  assurance  regarding the reliability of financial  reporting and the
preparation  of financial  statements for external  purposes in accordance  with
generally accepted  accounting  principles.  Our internal control over financial
reporting includes those policies and procedures that:

                                       14

<PAGE>

     (i)  pertain to the  maintenance  of records that,  in  reasonable  detail,
          accurately and fairly reflect the transactions and dispositions of our
          assets;

     (ii) provide  reasonable   assurance  that  transactions  are  recorded  as
          necessary to permit preparation of financial  statements in accordance
          with generally accepted accounting  principles,  and that our receipts
          and expenditures are being made only in accordance with authorizations
          of our management and directors; and

     (iii)provide reasonable  assurance regarding prevention or timely detection
          of  unauthorized  acquisition,  use or  disposition of our assets that
          could have a material effect on our financial statements.

Management's  assessment of the  effectiveness  of the small  business  issuer's
internal control over financial  reporting is as of the quarter ended August 31,
2008. We believe that internal control over financial reporting is effective. We
have not identified any, current material weaknesses  considering the nature and
extent of our current operations and any risks or errors in financial  reporting
under current operations.

Because of its inherent  limitations,  internal control over financial reporting
may not prevent or detect misstatements.  Also, projections of any evaluation of
effectiveness to future periods are subject to the risk that controls may become
inadequate  because of changes in  conditions,  or that the degree of compliance
with the policies or procedures may deteriorate.

There  was no change in our  internal  control  over  financial  reporting  that
occurred  during the fiscal  quarter ended August 31, 2008,  that has materially
affected,  or is reasonably  likely to materially  affect,  our internal control
over financial reporting.


                           PART II. OTHER INFORMATION

ITEM 1.  LEGAL PROCEEDINGS

No legal proceedings are pending or threatened to the best of our knowledge.

ITEM 2.  CHANGES IN SECURITIES

The Board of  Directors of the  Registrant  on  September  10,  2008,  adopted a
resolution  approving  a one for twenty  reverse  split of our  Common  Stock to
holders of record as of July 25,  2008.  The reverse  stock split  combines  our
outstanding  Common Stock on the basis of 20  outstanding  shares being combined
into one  outstanding  share.  Each  shareholder's  percentage  ownership in the
Registrant  (and relative voting power) will remain  essentially  unchanged as a
result of the reverse stock split.

The  resolution  provides that  fractional  shares will be rounded up so that no
shareholder  will be cashed out. The reverse  stock split was approved by 57.18%
of the shareholders.

ITEM 3.  DEFAULTS UPON SENIOR SECURITIES

None

ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

On September 12, 2008, we filed a Definitive  Information  Statement on Schedule
14C where we informed our  shareholders  that a majority of our shareholders had
approved two  resolutions by written  consent in lieu of a shareholder  meeting.
They approved a 1 for 20 reverse split of the Company's common stock.  They also
approved a change of the Company's name from Xpention  Genetics,  Inc. to Cancer
Detection Corporation.

                                       15

<PAGE>

ITEM 5. OTHER INFORMATION

None

ITEM 6.  EXHIBITS

Exhibits.  The  following is a complete  list of exhibits  filed as part of this
Form 10-Q.  Exhibit  numbers  correspond  to the numbers in the Exhibit Table of
Item 601 of Regulation S-K.

     Exhibit 31     Certification of Chief Executive Officer pursuant to Section
                    302 of the Sarbanes-Oxley Act

     Exhibit 32     Certification  of Principal  Executive  Officer  pursuant to
                    Section 906 of the Sarbanes-Oxley Act



















                                       16

<PAGE>



                                   SIGNATURES

In accordance with the requirements of Section 12 of the Securities Exchange Act
of 1934, the Registrant has duly caused this Registration Statement to be signed
on its behalf by the undersigned, thereunto duly authorized.

                                       CANCER DETECTION CORPORATION




Date: October 20, 2008                  By: /s/ David Kittrell
                                            ---------------------------
                                            David Kittrell
                                            Chief Executive Officer, &
                                            Chief Financial Officer


















                                       17